论文部分内容阅读
近年来，新辅助治疗在胰腺癌综合治疗中的作用日益受到重视。越来越多的证据表明，新辅助治疗有助于提高根治性（R0）切除率并改善患者预后。但目前新辅助治疗在胰腺癌患者中的应用指征、方案选择、疗效评估等仍有较大争议，临床应用尚不十分成熟。本文基于胰腺癌新辅助治疗的最新研究进展，分析胰腺癌新辅助治疗的临床实施难点，探讨科学合理的胰腺癌新辅助治疗模式。“,”In recent years, more and more attention has been paid on the role of neoadjuvant therapy in the comprehensive treatment of pancreatic cancer. There is increasing evidence indicates that neoadjuvant therapy improves the R0 resection rate and patient′s prognosis. However, the indication, therapy selection and efficacy evaluation of neoadjuvant therapy in patients with pancreatic cancer are still controversial, thus its clinical application is not very mature. This article aims to analyze the clinical implementation dilemma of neoadjuvant therapy for pancreatic cancer, and discuss the scientific and reasonable neoadjuvant treatment mode for pancreatic cancer patients.